logo
Twitter
Discord
Email
logo
High Tide Inc.

High Tide Inc.

NASDAQ•HITI
CEO: Mr. Harkirat Grover
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Listing Date: 2021-01-08
High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Retail and Wholesale segments. It operates licensed retail cannabis stores; and provides data analytics services. In addition, the company manufactures and distributes consumption accessories. Further, it sells its products through online sales via e-commerce platform. The company offers its products under the Daily High Club, DankStop, FABCBD, GC, Nuleaf, Smoke Cartel, and Blessed CBD brands. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. High Tide Inc. was founded in 2009 and is headquartered in Calgary, Canada.
Contact Information
11127 - 15 Street N.E., Unit 112, Calgary, AB, T3K 2M4, Canada
403-770-9435
www.hightideinc.com
Market Cap
$221.26M
P/E (TTM)
-29.0
240.6
Dividend Yield
--
52W High
$4.06
52W Low
$1.64
52W Range
37%
Rank52Top 73.5%
2.9
F-Score
Modified Piotroski Analysis
Based on 9-year fundamentals
Weak • 2.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2025

Financial Dashboard

Q3 2025 Data

Revenue

$108.93M+13.67%
4-Quarter Trend

EPS

$0.01-16.85%
4-Quarter Trend

FCF

$6.13M+205.88%
4-Quarter Trend

2024 FY Earnings Highlights

Key Highlights

Annual Report Amendment Filed Amendment No. 3 filed April 23, 2025, correcting typographical date errors in Annual Information Form exhibit 99.3.
Common Shares Outstanding Issuer reported 80,787,017 common shares outstanding at fiscal year end October 31, 2024 period close.
NASDAQ Listed Issuer High Tide Inc. common shares trade on NASDAQ Capital Market under ticker symbol HITI for investors.

Risk Factors

Filing Correction Required Typographical date errors required Amendment No. 3 filing, impacting initial report timeline perception for investors.
Foreign Private Issuer Status Operating as Foreign Private Issuer means compliance path differs from domestic U.S. GAAP filers requirements.
XBRL Data Submission Required Inline XBRL data files submitted, ensuring compliance with interactive data reporting mandates for SEC filings.

Outlook

Future Financial Filings Expect subsequent filings to adhere strictly to deadlines, incorporating new SOX certifications requirements moving forward.
Continued NASDAQ Listing Maintaining listing on NASDAQ Capital Market requires ongoing adherence to exchange rules and disclosure standards.
GAAP Transition Status Emerging Growth Company status allows potential extended transition periods for new or revised financial accounting standards.

Peer Comparison

Revenue (TTM)

The Oncology Institute, Inc.TOI
$461.04M
+21.7%
High Tide Inc.HITI
$407.32M
+11.2%
TruBridge, Inc.TBRG
$349.88M
+3.6%

Gross Margin (Latest Quarter)

Alector, Inc.ALEC
100.0%
+0.0pp
LifeMD, Inc.LFMD
87.7%
-32.4pp
RxSight, Inc.RXST
79.9%
+24.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CERS$478.30M-29.9-27.9%45.6%
SLP$419.85M-6.5-45.5%0.4%
RXST$391.02M-10.9-12.8%3.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Jan 29, 2026
|
EPS:-
|
Revenue:$158.91M
Reports
All Years

  • Form 40-F/A - FY 2024

    Period End: Oct 31, 2024|Filed: Apr 24, 2025|
    Revenue: $375.74M+7.1%
    |
    EPS: $-0.04+89.7%
    Miss

  • Form 40-F/A - FY 2024

    Period End: Oct 31, 2024|Filed: Mar 26, 2025|Refer to amended data

  • Form 40-F/A - FY 2024

    Period End: Oct 31, 2024|Filed: Jan 30, 2025|Refer to amended data

  • Form 40-F - FY 2024

    Period End: Oct 31, 2024|Filed: Jan 29, 2025|Refer to amended data

  • Form 40-F/A - FY 2023

    Period End: Oct 31, 2023|Filed: Jul 16, 2024|
    Revenue: $353.75M+36.7%
    |
    EPS: $-0.38+53.1%
    Miss

  • Form 40-F - FY 2023

    Period End: Oct 31, 2023|Filed: Jan 29, 2024|Refer to amended data

  • Form 40-F/A - FY 2022

    Period End: Oct 31, 2022|Filed: Feb 15, 2023|
    Revenue: $262.39M+97.0%
    |
    EPS: $-0.83-36.1%
    Miss

  • Form 40-F - FY 2022

    Period End: Oct 31, 2022|Filed: Jan 31, 2023|Refer to amended data